泓博医药 reported revenue of ¥0.36B for the period ended 2026-06-30, +3.3% year on year. Net income was ¥0.03B, a 7.9% net margin on a 27.9% gross margin. The largest revenue line is 药物发现 at 68% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.36B | +3.3% |
| Gross profit | ¥0.10B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | +16.0% |
| Gross margin | 27.9% | Net margin 7.9% |
| Revenue Q/Q | +11.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药物发现 | ¥0.25B | 67.6% |
| 商业化生产 | ¥0.06B | 16.9% |
| 工艺研究与开发 | ¥0.05B | 13.0% |
| 其他业务 | ¥0.01B | 2.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.26B | 72.1% |
| R&D | ¥0.02B | 5.7% |
| SG&A | ¥0.06B | 15.6% |
| Tax & other | ¥0.00B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥1.30B |
| Total liabilities | ¥0.29B |
| Shareholders' equity | ¥1.01B |
| Equity / assets | 77.7% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 251% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
荣信文化 ・ 飞沃科技 ・ 盛帮股份 ・ 五洲医疗 ・ 华康洁净 ・ 和顺科技 ・ 瑞泰新材 ・ 普瑞眼科 ・ 宏源药业 ・ 杰创智能 ・ 威尔高 ・ 同星科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies